| Company Name: | CYTYC Corporation | | Ticker Symbol: | CYTC | | | WWW Address: | www.cytyc.com |
| CEO: | Patrick J. Sullivan | | No. of Employees: | 1,500 |
| Common Issue Type: | CS | | Business Description: | A diversified diagnostic and medical device company that designs, develops, manufactures, and markets innovative and clinically effective diagnostic and surgical products.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | | | | | | 51.45 | 50.31 | |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 0.0 | 116.7 | -0.11 | 1.16 | 0.00 | 105.0 | 0.0 | 52.33 - 25.80 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 50.41 | $ | | PE Ratio - LTM | 105.0 | |
| Market Capitalisation | 0.0 | mil |
| Latest Shares Outstanding | 116.7 | mil |
| Earnings pS (EPS) | 1.16 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 405,500 | $ |
| Effective Tax Rate | 35.0 | % |
| Float | 116.2 | mil |
| Float as % of Shares Outstanding | 99.6 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 6.50 | % |
| Gross Profit Margin | 82.9 | % |
| EBITDA Margin | 39.2 | % |
| Pre-Tax Profit Margin | 20.4 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | 4.7 | % |
| Return on Equity (ROE) | 7.7 | % |
| Return on Capital Invested (ROCI) | 5.8 | % |
| Current Ratio | 1.6 | |
| Leverage Ratio (Assets/Equity) | 1.6 | |
| Interest Cover | 14.6 | |
| Total Debt/Equity (Gearing Ratio) | 0.39 | |
| LT Debt/Total Capital | 24.0 | % |
| Working Capital pS | 0.70 | $ |
| Cash pS | 0.27 | $ |
| Book-Value pS | 6.78 | $ |
| Tangible Book-Value pS | -1.03 | $ |
| Cash Flow pS | 0.92 | $ |
| Free Cash Flow pS | -3.02 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.44 | |
| Price/Tangible Book Ratio | -48.94 | |
| Price/Cash Flow | 54.8 | |
| Price/Free Cash Flow | -16.7 | |
| P/E as % of Industry Group | 382.0 | % |
| P/E as % of Sector Segment | 216.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
| 
|  | | Share price performance intraday |
| 
| |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.5 | 98 | 17,997 | 49,436 |
| 4 Weeks | 52.33 | 47.84 | 47.65 | 5.8 | 106 | 16,824 | 286,009 |
| 13 Weeks | 52.33 | 39.30 | 42.85 | 17.6 | 113 | 14,893 | 908,503 |
| 26 Weeks | 52.33 | 34.29 | 36.63 | 37.6 | 135 | 18,395 | 2,280,964 |
| 52 Weeks | 52.33 | 25.80 | 26.03 | 93.7 | 176 | 13,625 | 3,365,350 |
| YTD | 52.33 | 27.80 | - | 78.1 | 166 | 14,716 | 3,002,122 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 50.92 | 51.03 | 45.55 | 41.59 | 38.72 | -0.11 | 1.62 |
|
| |
| GROWTH RATES | 5-Year Growh | R² of 5-Year Growth | 3-Year Growth |
| Revenue | 23.50 | 97.6 | 20.92 |
| Income | 0.00 | 0.0 | 8.21 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 62.70 | NA | 59.91 |
| R&D | 25.25 | NA | 36.14 |
| Normalized Inc. | 21.42 | NA | 19.59 |
| | | CHANGES | YTD vs. Last YTD | Curr Qtr vs. Qtr 1-Yr ago | Annual vs. Last Annual |
| Revenue % | 23.0 | 25.6 | 19.7 |
| Earnings % | -100.0 | 5.9 | 23.0 |
| EPS % | -100.0 | 0.0 | 23.4 |
| EPS $ | -0.66 | 0.00 | 0.22 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 31.17 |
| Current Ratio | 5.9 |
| Quick Ratio (Acid Test) | 5.3 |
| Liquidity Ratio (Cash) | 4.02 |
| Receivables Turnover | 6.8 |
| Average Collection Period | 53 |
| Working Capital/Equity | 47.8 |
| Working Capital pS | 3.16 |
| Cash-Flow pS | 1.53 |
| Free Cash-Flow pS | 0.90 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 10.37 |
| Financial Leverage Ratio (Assets/Equity) | 1.5 |
| Debt Ratio | 34.8 |
| Total Debt/Equity (Gearing Ratio) | 0.33 |
| LT Debt/Equity | 0.33 |
| LT Debt/Capital Invested | 32.9 |
| LT Debt/Total Liabilities | 61.6 |
| Interest Cover | 29.6 |
| Interest/Capital Invested | 0.69 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 99.11 |
| Tobin's Q Ratio | 5.05 |
| Current P/E Ratio - LTM | 105.00 |
| Enterprise Value (EV)/EBITDA | 24.92 |
| Enterprise Value (EV)/Free Cash Flow | 59.77 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -48.94 |
| Price/Book Ratio - LTM | 7.44 |
| Price/Cash Flow Ratio | 54.8 |
| Price/Free Cash Flow Ratio - LTM | -16.7 |
| Price/Sales Ratio | 8.71 |
| P/E Ratio (1 month ago) - LTM | 92.9 |
| P/E Ratio (26 weeks ago) - LTM | 31.6 |
| P/E Ratio (52 weeks ago) - LTM | 25.0 |
| 5-Y High P/E Ratio | 71.8 |
| 5-Y Low P/E Ratio | 13.6 |
| 5-Y Average P/E Ratio | 29.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 362 |
| P/E as % of Industry Group | 382.0 |
| P/E as % of Sector Segment | 216.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 41.7 |
| PER SHARE FIGURES |
| LT Debt pS | 2.18 |
| Current Liabilities pS | 0.65 |
| Tangible Book Value pS - LTM | -1.03 |
| Book Value pS - LTM | 6.78 |
| Capital Invested pS | 8.65 |
| Cash pS - LTM | 0.27 |
| Cash Flow pS - LTM | 0.92 |
| Free Cash Flow pS - LTM | -3.02 |
| Earnings pS (EPS) | 1.16 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 17.03 |
| Free Cash Flow Margin 5YEAR AVG | 4.34 |
| Net Profit Margin | 22.9 |
| Net Profit Margin - 5YEAR AVRG. | 22.0 |
| Equity Productivity | 0.80 |
| Return on Equity (ROE) | 18.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 17.7 |
| Capital Invested Productivity | 0.60 |
| Return on Capital Invested (ROCI) | 13.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 13.6 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 12.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 12.0 |
| Gross Profit Margin | 82.9 |
| Gross Profit Margin - 5YEAR AVRG. | 83.7 |
| EBITDA Margin - LTM | 39.2 |
| EBIT Margin - LTM | 21.9 |
| Pre-Tax Profit Margin | 35.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 35.5 |
| Effective Tax Rate | 35.0 |
| Effective Tax Rate - 5YEAR AVRG. | 38.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 154 |
| Revenue per Employee | 405,500 |
| Net Income per Employee | 93,025 |
| Average Collection Period | 56 |
| Receivables Turnover | 6.8 |
| Day's Inventory Turnover Ratio | 98 |
| Inventory Turnover | 3.7 |
| Inventory/Sales | 4.9 |
| Accounts Payble/Sales | 2.06 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.68 |
| Fixed Assets Turnover | 0.84 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 4.32 |
| Revenue per $ Plant | 4.08 |
| Revenue per $ Common Equity | 0.80 |
| Revenue per $ Capital Invested | 0.60 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 36.1 |
| Research & Devlopment (R&D) as % of Revenue | 7.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.3 |
|
|  





|
| |
 |  |